semaglutide
Evaluating Cost‑Efficacy of Semaglutide in MC4R‑Deficient Obesity
In the pivotal phase-3 MC4R-deficient trial, semaglutide produced a 21.3% weight loss, about 59 kg for a 220-lb adult, which translates to roughly 0.04 lb per $1 spent at its $3,390 annual price. This metric helps clinicians and patients gauge cost-efficiency before initiating therapy. Medical Disclaimer: This